CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2016 Apr 15

PMID 27074923

Citations 5

Authors

Guijuan Zong

Zhiwei Xu

Shusen Zhang

Yifen Shen

Huiyuan Qiu

Guizhou Zhu

Song He

Tao Tao

Xudong Chen

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) accounts for 75-80 % of primary liver cancer, and usually arises after years of liver disease. Thus it is important to understand the molecular mechanisms which drive or mediate the development of HCC.

Aim: In this work, we examined whether CD109 was associated with a poor prognosis in HCC and explored possible underlying mechanisms.

Methods: We examined the CD109 and Ki67 expression levels in 97 patients with HCC using immunohistochemistry. CD109 levels in HCC cells were down-regulated by shRNA transfection. The cycle progression and cell proliferation status of HCC cells were evaluated by flow cytometry and CCK-8 assay. The effect of CD109 on proliferation and apoptosis was investigated by western blot and TUNEL activity assays.

Results: The CD109 protein was up-regulated in HCC tissue compared with adjacent noncancerous tissue. CD109 expression levels in the 97 patients with HCC were positively correlated with histological grade. Univariate and multivariate survival analysis revealed that CD109 was a significant predictor of overall survival among HCC patients. CD109 shRNA knockdown delayed the G1-S phase transition, abrogated cell proliferation, and increased cell apoptosis. Furthermore, CD109 impaired TGF-β/Smad signaling through control of p-smad2.

Conclusions: CD109 promoted HCC proliferation and predicted poor prognosis. In addition, CD109 expression was associated with anti-apoptosis in HCC cells.

Citing Articles

CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.

Mo X, Leung T, Tang H, Siu M, Wan P, Chan K Br J Cancer. 2020; 123(5):833-843.

PMID: 32507856 PMC: 7463003. DOI: 10.1038/s41416-020-0922-7.

Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.

Lee K, Shueng P, Chou C, Lin B, Lin M, Kuo D Cancer Sci. 2020; 111(5):1652-1662.

PMID: 32133706 PMC: 7226182. DOI: 10.1111/cas.14373.

Retraction Note: CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.

Zong G, Xu Z, Zhang S, Shen Y, Qiu H, Zhu G Dig Dis Sci. 2019; 64(12):3676.

PMID: 31713120 DOI: 10.1007/s10620-019-05932-9.

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.

Arias-Pinilla G, Dalgleish A, Mudan S, Bagwan I, Walker A, Modjtahedi H Oncotarget. 2018; 9(28):19994-20007.

PMID: 29731998 PMC: 5929441. DOI: 10.18632/oncotarget.25017.

Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy.

Gong Y, Zhang J, Wu X, Wang T, Zhao J, Yao Z Oncol Lett. 2017; 14(4):4158-4166.

PMID: 28943923 PMC: 5592876. DOI: 10.3892/ol.2017.6724.

References

Sciarra A, Di Tommaso L, Nakano M, Destro A, Torzilli G, Donadon M . Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol. 2015; 64(1):87-93. DOI: 10.1016/j.jhep.2015.08.031. View

Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H . Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene. 2010; 29(15):2181-91. DOI: 10.1038/onc.2009.506. View

Zhang J, Murakumo Y, Hagiwara S, Jiang P, Mii S, Kalyoncu E . CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys Res Commun. 2015; 459(2):252-258. DOI: 10.1016/j.bbrc.2015.02.093. View

Cuppini L, Calleri A, Bruzzone M, Prodi E, Anghileri E, Pellegatta S . Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One. 2013; 8(9):e74345. PMC: 3772091. DOI: 10.1371/journal.pone.0074345. View

Litvinov I, Bizet A, Binamer Y, Jones D, Sasseville D, Philip A . CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol. 2011; 20(8):627-32. DOI: 10.1111/j.1600-0625.2011.01288.x. View

Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N . Expression of CD109 in human cancer. Oncogene. 2004; 23(20):3716-20. DOI: 10.1038/sj.onc.1207418. View

Hwang S, Kim M, Chang H, Hong Y, Kim T, Song E . Human platelet antigen genotyping and expression of CD109 (human platelet antigen 15) mRNA in various human cell types. Biomed Res Int. 2013; 2013:946403. PMC: 3583088. DOI: 10.1155/2013/946403. View

Yan H, Jiang J, Pang Y, Achyut B, Lizardo M, Liang X . CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. Cancer Res. 2015; 75(24):5283-98. PMC: 5120555. DOI: 10.1158/0008-5472.CAN-15-2282-T. View

Tsao C, Yan M, Shih Y, Yu P, Kuo C, Lin W . SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma. Hepatology. 2012; 56(6):2277-87. DOI: 10.1002/hep.25933. View

10.

Winocour S, Vorstenbosch J, Trzeciak A, Lessard L, Philip A . CD109, a novel TGF-β antagonist, decreases fibrotic responses in a hypoxic wound model. Exp Dermatol. 2014; 23(7):475-9. DOI: 10.1111/exd.12439. View

11.

Zhang F, Lin H, Gu A, Li J, Liu L, Yu T . SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC. J Proteomics. 2014; 102:125-36. DOI: 10.1016/j.jprot.2014.03.007. View

12.

Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J . CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol. 2014; 41(10):947-9. DOI: 10.1111/1346-8138.12620. View

13.

Ohshima Y, Yajima I, Kumasaka M, Yanagishita T, Watanabe D, Takahashi M . CD109 expression levels in malignant melanoma. J Dermatol Sci. 2009; 57(2):140-2. DOI: 10.1016/j.jdermsci.2009.11.004. View

14.

Zhang J, Fan D, Jian Z, Chen G, Lai P . Cancer Specific Long Noncoding RNAs Show Differential Expression Patterns and Competing Endogenous RNA Potential in Hepatocellular Carcinoma. PLoS One. 2015; 10(10):e0141042. PMC: 4619599. DOI: 10.1371/journal.pone.0141042. View

15.

Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S . Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010; 60(11):735-43. DOI: 10.1111/j.1440-1827.2010.02592.x. View

16.

van den Hoogen C, van der Horst G, Cheung H, Buijs J, Lippitt J, Guzman-Ramirez N . High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 2010; 70(12):5163-73. DOI: 10.1158/0008-5472.CAN-09-3806. View

17.

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp H, Walenkamp A . Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB.... Br J Cancer. 2015; 113(2):226-31. PMC: 4506382. DOI: 10.1038/bjc.2015.191. View

18.

Zhang S, Shi W, Chen Y, Xu Z, Zhu J, Zhang T . Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma. Mol Cell Biochem. 2015; 410(1-2):1-9. DOI: 10.1007/s11010-015-2533-9. View

19.

Cheng A, Lau S, Chen Y, Kondo Y, Li M, Feng H . EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011; 71(11):4028-39. DOI: 10.1158/0008-5472.CAN-10-3342. View

20.

Lin M, Sutherland D, Horsfall W, Totty N, Yeo E, Nayar R . Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood. 2002; 99(5):1683-91. DOI: 10.1182/blood.v99.5.1683. View